Anti-leishmanial activity of a new formulation of amphotericin B

Tropical Medicine and International Health

Volumn 9, Issue 9, 2004, Pages 981-990

  Dea Ayuela, M A ^a,b   Rama Iniguez S ^a,b   Sanchez Brunete J A ^a,b   Torrado, J J ^a,b   Alunda, J M ^a   Bolas Fernandez F ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Albumin microspheres; Amphotericin B; Hamster model; Leishmaniasis

Indexed keywords

ALBUMIN; AMPHOTERICIN B; LIPOSOME; MICROSPHERE;

ANTIBODY; DISEASE CONTROL; LEISHMANIASIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; ENCAPSULATION; HAMSTER; LIVER; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROMASTIGOTE; SPLEEN; VISCERAL LEISHMANIASIS;

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS; PROTOZOA;

EID: 4644239395     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01296.x     Document Type: Article

References (32)

1. Bradford M (1976) A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72, 248-250.
2. Berman JD, Hanson WL, Chapman WL, Alving CR & Lopez-Berestein G (1986) Antileishmanial activity of liposome encapsulated amphotericin B in hamsters and monkeys. Antimicrobial Agents and Chemotherapy 30, 847-851.
3. Bourdoiseau G, Bonnefont C, Hoareau E, Boehringer C, Stolle T & Chabanne L (1997) Specific IgG1 and IgG2 antibody and lymphocyte subsets levels in naturally Leishmania infantum-infected treated and untreated dogs. Veterinary Immunology and Immunopathology 59, 21-30.
4. Bryceson A (2001a) Current issues in the treatment of visceral leishmaniasis. Medical Microbiology and Immunology 190, 81-84.
5. Bryceson A (2001b) A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 6, 928-934.
6. Conte U, Giunchedi P, Maggi L & Torre ML (1994) Spray dried albumin microspheres containing nicardipine. European Journal of Pharmaceutics and Biopharmaceutics 40, 203-208.
7. Coukell AJ & Brogden RN (1998) Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55, 585-612.
8. Croft SL (1997) Current status of antiparasitic chemotherapy. Parasitology 114, S3-S15.
9. Durand R, Paul M, Rivollet D, Houin R, Astier A & Deniau M (1997) Activity of pentamidine loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. International Journal for Parasitology 27, 1361-1367.
10. Echevarria I, Barturen C, Renedo MJ, Troconiz IF & Dios-Vieitez MC (2000) Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrobial Agents and Chemotherapy 44, 898-904.
11. Gangneux JP (1999) Treatment of visceral leishmaniasis: recent modalities. Presse Medicale 28, 2057-2066.
12. Gangneux JP, Sulahian A, Garin YJ, Farinotti R & Derouin F (1996) Therapy of visceral leihsmaniasis due to Leishmania infantum: experimental assessment of efficacy of ambisome. Antimicrobial Agents and Chemotherapy 40, 1214-1218.
13. Gaspar R, Opperdoes FR, Preat V & Roland M (1992) Drug targeting with polyalkylcyanocrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Annals of Tropical Medicine and Parasitology 86, 41-49.
14. Gradoni L, Gramiccia M & Pozio E (1984) Status of the taxonomy of Leishmania from the Mediterranean basin. Parassitologia 26, 289-297.
15. Hide M, Banuls AL & Tibayrenc M (2001) Genetic heterogeneity and phylogenetic status of Leishmania (Leishmania) infantum zymodeme MON-1: epidemiological implications. Parasitology 123, 425-432.
16. Kratz F, Roth T, Fichiner I et al. (2000) In vitro and In vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model. Journal of Drug Targeting 8, 305-318.
17. Marty P & Rosenthal E (2002) Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opinion in Pharmacotherapy 3, 1101-1108.
18. Moreno J, Nieto J, Chamizo C et al. (1999) The immune response and PBMC subsets in canine visceral leishmaniasis before, and after chemotherapy. Veterinary Immunology and Immunopathology 71, 181-195.
19. Mullen AB, Carter KC & Baillie AJ (1997) Comparison of the efficacies of various formulations of amphotericin B against marine visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 2089-2092.
20. Muriel P, Durand R, Fessi H et al. (1997) Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a marine model. Antimicrobial Agents and Chemotherapy 41, 1731-1734.
21. New RRC, Chance M & Heath S (1983). Liposomal therapy for experimental cutaneous and visceral leishmaniasis. Biology of the Cell 47, 59-64.
22. Proffitt RT, Satorius A, Chiang SM, Sullivan L & Adler-Moore JP (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 28 (Suppl. B), 49-61.
23. Ravi-Kumar MN (2000) Nano and microparticles as controlled drug delivery devices. Journal of Pharmacy and Pharmaceutical Sciences 3, 234-258.
24. Senior J (1987) Fate and behaviour of liposomes in vivo: a review of controlling factors. Critical Review of Therapeutical Drug Carrier Systems 3, 123-193.
25. Stauber LA, Franchino EM & Grun J (1958) An eight-day method for screening compounds against Leishmania donovani in golden hamsters. Journal of Protozoology 5, 269-273.
26. Sundar S (2001) Treatment of visceral leishmaniasis. Medical Microbiology and Immunology 190, 89-92.
27. Sundar S, Goyal AK, More DK & Singh MK (1998) Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultrashort courses of amphotericin B lipid complex. Annals of Tropical Medicine and Parasitology 92, 755-764.
28. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 1739-1746.
29. Torre-Cisneros J, Prada JL, Kindelán JM, Jurado R & Sánchez-Guijo P (1994) Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 17, 625-627.
30. Vercammen F, Fernández-Pérez FJ, del Amo C & Alunda JM (2002) Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot. Acta Tropica 84, 175-181.
31. Yardley V & Croft S (1997) Activity of liposomal amphotericin B against experimental cutaneous leishmanisiasis. Antimicrobial Agents and Chemotherapy 41, 752-756.
32. Yardley V & Croft SL (2000) A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. International Journal of Antimicrobial Agents 13, 243-248.